Literature DB >> 31161341

Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Mohan S Maddur1, Sébastien Lacroix-Desmazes1, Jordan D Dimitrov1, Michel D Kazatchkine2, Jagadeesh Bayry1, Srini V Kaveri3.   

Abstract

Natural antibodies (nAbs) are most commonly defined as immunoglobulins present in the absence of pathological conditions or deliberate immunizations. Occurrence of nAbs in germ- and antigen-free mice suggest that their production is driven, at least in part, by self-antigens. Accordingly, nAbs are constituted of natural autoantibodies (nAAbs), and can belong to the IgM, IgG, or IgA subclasses. These nAbs provide immediate protection against infection while the adaptive arm of the immune system mounts a specific and long-term response. Beyond immediate protection from infection, nAbs have been shown to play various functional roles in the immune system, which include clearance of apoptotic debris, suppression of autoimmune and inflammatory responses, regulation of B cell responses, selection of the B cell repertoires, and regulation of B cell development. These various functions of nAbs are afforded by their reactivity, which is broad, cross-reactive, and shown to recognize evolutionarily fixed epitopes shared between foreign and self-antigens. Furthermore, nAbs have unique characteristics that also contribute to their functional roles and set them apart from antigen-specific antibodies. In further support for the role of nAbs in the protection against infections and in the maintenance of immune homeostasis, the therapeutic preparation of polyclonal immunoglobulins, intravenous immunoglobulin (IVIG), rich in nAbs is commonly used in the replacement therapy of primary and secondary immunodeficiencies and in the immunotherapy of a large number of autoimmune and inflammatory diseases. Here, we review several topics on nAbs features and functions, and therapeutic applications in human diseases.

Entities:  

Keywords:  Autoimmunity; IVIG; Immune homeostasis; Intravenous immunoglobulin; Natural IgG; Natural IgM; Therapy

Year:  2020        PMID: 31161341     DOI: 10.1007/s12016-019-08746-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  109 in total

Review 1.  Intravenous immunoglobulin: exploiting the potential of natural antibodies.

Authors:  Srini V Kaveri
Journal:  Autoimmun Rev       Date:  2012-02-12       Impact factor: 9.754

2.  Emil von Behring, born March 15, 1854.

Authors:  A S MACNALTY
Journal:  Br Med J       Date:  1954-03-20

Review 3.  What is the contents of the magic draft IVIg?

Authors:  Jean-François Seite; Yehuda Shoenfeld; Pierre Youinou; Sophie Hillion
Journal:  Autoimmun Rev       Date:  2008-05-02       Impact factor: 9.754

4.  Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.

Authors:  Mohan S Maddur; Jamma Trinath; Magalie Rabin; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Kithiganahalli N Balaji; Srini V Kaveri; Jagadeesh Bayry
Journal:  Cell Mol Immunol       Date:  2014-12-08       Impact factor: 11.530

Review 5.  Intravenous immunoglobulin as clinical immune-modulating therapy.

Authors:  Laurent Gilardin; Jagadeesh Bayry; Srini V Kaveri
Journal:  CMAJ       Date:  2015-02-09       Impact factor: 8.262

Review 6.  Intravenous immune globulin in autoimmune and inflammatory diseases.

Authors:  Erwin W Gelfand
Journal:  N Engl J Med       Date:  2012-11-22       Impact factor: 91.245

Review 7.  Passive Serum Therapy to Immunomodulation by IVIG: A Fascinating Journey of Antibodies.

Authors:  Cristina João; Vir Singh Negi; Michel D Kazatchkine; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Immunol       Date:  2018-03-15       Impact factor: 5.422

8.  Regulatory T cells induce activation rather than suppression of human basophils.

Authors:  Meenu Sharma; Mrinmoy Das; Emmanuel Stephen-Victor; Caroline Galeotti; Anupama Karnam; Mohan S Maddur; Patrick Bruneval; Srini V Kaveri; Jagadeesh Bayry
Journal:  Sci Immunol       Date:  2018-05-25

9.  Defining Natural Antibodies.

Authors:  Nichol E Holodick; Nely Rodríguez-Zhurbenko; Ana María Hernández
Journal:  Front Immunol       Date:  2017-07-26       Impact factor: 7.561

10.  Monomeric Immunoglobulin A from Plasma Inhibits Human Th17 Responses In Vitro Independent of FcαRI and DC-SIGN.

Authors:  Chaitrali Saha; Mrinmoy Das; Veerupaxagouda Patil; Emmanuel Stephen-Victor; Meenu Sharma; Sandra Wymann; Monika Jordi; Cédric Vonarburg; Srini V Kaveri; Jagadeesh Bayry
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

View more
  18 in total

Review 1.  Innate B Cells: the Archetype of Protective Immune Cells.

Authors:  Alexis Grasseau; Marina Boudigou; Laëtitia Le Pottier; Nedra Chriti; Divi Cornec; Jacques-Olivier Pers; Yves Renaudineau; Sophie Hillion
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

2.  Role of B1 and B2 lymphocytes in placental ischemia-induced hypertension.

Authors:  Connor F Laule; Evan J Odean; Cameron R Wing; Kate M Root; Kendra J Towner; Cassandra M Hamm; Jeffrey S Gilbert; Sherry D Fleming; Jean F Regal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-09       Impact factor: 4.733

Review 3.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

4.  Commentary: Immunology's Coming of Age.

Authors:  Heinz Kohler; Anastas Dimitrov Pashov; Thomas Kieber-Emmons
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

5.  Early infection-induced natural antibody response.

Authors:  Klara Kubelkova; Tomas Hudcovic; Hana Kozakova; Jaroslav Pejchal; Ales Macela
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

6.  Toll-Like Receptor Homolog CD180 Expression Is Diminished on Natural Autoantibody-Producing B Cells of Patients with Autoimmune CNS Disorders.

Authors:  Zsófia Hayden; Szabina Erdő-Bonyár; Beáta Bóné; Noémi Balázs; Kornélia Bodó; Zsolt Illes; Timea Berki; Diána Simon
Journal:  J Immunol Res       Date:  2021-05-25       Impact factor: 4.818

Review 7.  B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells.

Authors:  Carlo G Bonasia; Wayel H Abdulahad; Abraham Rutgers; Peter Heeringa; Nicolaas A Bos
Journal:  Cells       Date:  2021-05-13       Impact factor: 6.600

8.  Increased Frequency of Activated Switched Memory B Cells and Its Association With the Presence of Pulmonary Fibrosis in Diffuse Cutaneous Systemic Sclerosis Patients.

Authors:  Diána Simon; Péter Balogh; Szabina Erdő-Bonyár; Katalin Böröcz; Tünde Minier; László Czirják; Tímea Berki
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 9.  Exploring the pathways to chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Francesco Forconi; Thomas J Kipps
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

10.  Immunoglobulins with Non-Canonical Functions in Inflammatory and Autoimmune Disease States.

Authors:  Evgeny A Ermakov; Georgy A Nevinsky; Valentina N Buneva
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.